Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Ladenburg Thalmann Downgrades Calithera Biosciences to Neutral

Ladenburg Thalmann analyst Aydin Huseynov downgrades Calithera Biosciences (NASDAQ:CALA) from Buy to Neutral.
byBenzinga Newsdesk
November 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Ladenburg Thalmann analyst Aydin Huseynov downgrades Calithera Biosciences (NASDAQ:CALA) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Clover Health Announces Business Transformation Initiatives To Accelerate Path To Profitability, Including An Agreement To Move Its Core Plan Operations To UST Healthproof’s Integrated Technology Platform And Additional Corporate Restructuring Actions

By Happy Mohamed
Today, 9:15 AM
 Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or "Clover Health" or "the company"), today announced business transformation initiatives to accelerate the company's path

CLOV